Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T P Poon

Showing results (221-230 of 228) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 228 results.
Gut|December 16, 2016
<i>TSC1/2</i> mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationDaniel W H Ho, Lo K Chan, Yung T Chiu, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021Tan-To Cheung, Simon Chun-Ho Yu, Stephen L Chan, et al.
Journal of Gastroenterology and Hepatology|June 15, 2012
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011Joseph J Y Sung, Enders K W Ng, Jaw-Town Lin, et al.
JAMA|July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialAndrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinomaXiao Qi Wang, John M Luk, Mercè Garcia-Barcelo, et al.
Hepatology International|September 10, 2010
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaMasao Omata, Laurentius A Lesmana, Ryosuke Tateishi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.
Plos One|July 14, 2011
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limitingJohn R Lamb, Chunsheng Zhang, Tao Xie, et al.
Pageof 23

Showing results (221-230 of 228) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 228 results.
Gut|December 16, 2016
<i>TSC1/2</i> mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationDaniel W H Ho, Lo K Chan, Yung T Chiu, et al.
Hepatobiliary Surgery and Nutrition|June 23, 2023
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021Tan-To Cheung, Simon Chun-Ho Yu, Stephen L Chan, et al.
Journal of Gastroenterology and Hepatology|June 15, 2012
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011Joseph J Y Sung, Enders K W Ng, Jaw-Town Lin, et al.
JAMA|July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trialAndrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinomaXiao Qi Wang, John M Luk, Mercè Garcia-Barcelo, et al.
Hepatology International|September 10, 2010
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaMasao Omata, Laurentius A Lesmana, Ryosuke Tateishi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPhilip J Johnson, Shukui Qin, Joong-Won Park, et al.
Plos One|July 14, 2011
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limitingJohn R Lamb, Chunsheng Zhang, Tao Xie, et al.
Pageof 23